Prospects for pharmacotherapy of schizophrenia (Q40401417)

20 September 2017

1 reference

title

Prospects for pharmacotherapy of schizophrenia (English)

1 reference

20 September 2017

0 references

0 references

D Pickar

1

1 reference

PubMed ID

7539875

20 September 2017

language of work or name

English

0 references

publication date

1 March 1995

1 reference

20 September 2017

1 reference

20 September 2017

345

1 reference

20 September 2017

8949

1 reference

20 September 2017

557-562

1 reference

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

The costs of schizophrenia. Assessing the burden.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

The current status of the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Perspectives on a time-dependent model of neuroleptic action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

The effects of clozapine on tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Effect of clozapine on human serum prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

In vivo studies of [125I]iodobenzamide and [11C]iodobenzamide: a ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Dopamine receptor occupancy and plasma haloperidol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Schizophrenia: a neurodevelopmental perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990469-7

7 January 2021

10.1016/S0140-6736(95)90469-7

Identifiers

DOI

1 reference

20 September 2017

1 reference

PubMed ID

7539875